Suppr超能文献

鼻咽癌的临床试验——过去、现在与未来

Clinical trials in nasopharyngeal carcinoma-past, present and future.

作者信息

Xu Cheng, Chen Yu-Pei, Ma Jun

机构信息

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, China.

出版信息

Chin Clin Oncol. 2016 Apr;5(2):20. doi: 10.21037/cco.2016.03.12.

Abstract

Nasopharyngeal carcinoma (NPC) has an age-adjusted incidence for both sexes with greater frequency in some endemic regions, especially the southern China. Genetic, ethnic, environmental factors and Epstein-Barr virus (EBV) infection might take part in the cause of the disease. Based on the understanding and research progresses, we have had a further step among the diagnosis and prognosis of the disease. Meanwhile, a numerous clinical trials aiming to pick out the most suitable therapeutic choice are carried on from past till now. The purpose of this review is to summarize therapeutic approaches from past RCTs, introduce hot topics at present, and explore the development trend in the future. Applying appropriate combining procedures of radiotherapy and chemotherapy with developments in gene therapy and immunotherapy, the outcomes in the future might be widely improved.

摘要

鼻咽癌(NPC)在调整年龄后,男女发病率均有差异,在一些高发地区更为常见,尤其是中国南方。遗传、种族、环境因素以及爱泼斯坦-巴尔病毒(EBV)感染可能参与了该疾病的病因。基于对该疾病的认识和研究进展,我们在其诊断和预后方面又向前迈进了一步。与此同时,从过去到现在,大量旨在筛选出最合适治疗方案的临床试验一直在进行。本综述的目的是总结过去随机对照试验(RCT)中的治疗方法,介绍当前的热点话题,并探索未来的发展趋势。随着基因治疗和免疫治疗的发展,应用适当的放疗和化疗联合方案,未来的治疗效果可能会得到广泛改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验